Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-15
2009-06-16
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S365000
Reexamination Certificate
active
07547678
ABSTRACT:
The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.
REFERENCES:
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 7320961 (2008-01-01), Kempf et al.
patent: 2004/0192624 (2004-09-01), Kempf et al.
patent: 2004/0242509 (2004-12-01), Kempf et al.
patent: WO2004/084892 (2004-10-01), None
S. Agarwala et al.,Steady State Pharmacokinetic(PK)Interaction Study of Atazanavir(ATV)with Ritonavir(RTV)in Healthy Subjects, Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 42:274 (2002) & poster H-1716 presented at 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, California, Sep. 27-30, 2002).
P. Baede et al.,Drug Interaction with TMC125, a Potent Next Generation NNRTI, Abstracts of The Interscience Conference on Antimicrobial Agents and Chemotherapy 42:27 (2002).
E. O'Mara et al., Steady-State Pharmacokinetic Interaction Study of Atazanavir (ATV) with Efavirenz (EPV) and Ritonavir (RTV) in Healthy Subjects, Programs and Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, abstract 444 (Seattle, Washington, Feb. 24-28, 2002).
E. O'Mara et al.,Relationship between Uridine Phosphate-Glucuronosyl Transferase(UDP-GT)1A1 Genotype and Total Bilirubin Elevations in Healthy Subjects Receiving BMS-232632 and Saquinavir, poster 1645 presented at 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Ontario, Canada, Sep. 17-20, 2000).
D. Oullet et al.,Effect of Ritonavir on the Pharmacokinetics of Ethinyl Oestradiol in Healthy Female Volunteers, British Journal of Clinical Pharmacology 46(2):111-6 (1998).
S.R. Penzak,Influence of Ritonavir on Olanzapine Pharmacokinetics in Healthy Volunteers, Journal of Clinical Psychopharmacology 22(4):366-70 (2002).
A. Radominska-Pandya et al.,Structural and Functional Studies of UDP-Glucoronosyltransferases, Drug Metabolism Reviews 31(4):817-99 (1999).
J.K. Ritter et al.,Expression and Inducibility of the Human Bilirubin UDP-Glucuronosyltransferase UGT1A1 in Liver and Cultured Primary Hepatocytes: Evidence for Both Genetic and Environmental Influences, Hepatology 30(2):476-84 (1999).
J. Sugatani et al.,The Phenobarbital Response Enhancer Module in the Human Bilirubin UDP-Glucuronosyltransferase UGT1A1 Gene and Regulation by the Nuclear Receptor CAR, Hepatology 33(5):1232-38 (2001).
R.H. Tukey et al.,Human UDP-Glucoronosyltransferases: Metabolism, Expression, and Disease, Ann. Rev. Pharmacol. Toxicol. 40:581-616 (2000).
S.D. Zucker et al.,Mechanism of Indinavir-Induced Hyperbilirubinemia, PNAS 98(22):12671-6 (2001).
Bertz Richard J.
Kempf Dale J.
Waring Jeffrey F.
Abbott Laboratories
Henley, III Raymond J
Nenow Lydia N.
Ward Michael J.
LandOfFree
Method for treating a disease, disorder or adverse effect... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a disease, disorder or adverse effect..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a disease, disorder or adverse effect... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084143